Business
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany
About this update from Alx Oncology Holdings Inc.
[{"type":"text","content":"Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on Friday, June 7, 2024, at 1:00 PM ET SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation (abstract #4575) at the 2024 American Society of Cancer Oncology (“ASCO”) Annual Meeting being held in Chicago from May 31-June 4, 2024. These findings represent the first evorpacept combination data with an ADC from ASPEN-07’s ongoing, open-label, single-arm, clinical trial of evorpacept in combination with PADCEV (enfortumab vedotin or “EV”) in patients with locally advanced or metastatic urothelial cancer (“la/m UC”). Evorpacept is a CD47 blocker with an inactivated Fc effector domain that is designed to minimize associated toxicity. Key results as of the data cut-off date of April 3, 2024: Initial patient demographics Twenty-eight EV-naïve patients were enrolled with 29% having received three or more prior lines of therapy.All patients had disease that progressed after platinum chemotherapy and checkpoint inhibition.Approximately 93% of patients had metastatic disease. The combination was generally well-tolerated in a heavily pre-treated patient population No maximum tolerated dose was reached, and the maximum administered evorpacept dose was 30 mg/kg Q2W.There were no treatment-related deaths in the study.The most frequent adverse events due to any cause were low-grade fatigue, dysgeusia, nausea, diarrhea, hyperglycemia, and pruritis. Initial activity showed tumor reduction in the majority of evaluable patients ASCO poster presentation data-cut reported an unconfirmed overall response rate (“ORR”) of 59% (n=22) with evorpacept plus EV (EV single agent ORR benchmark is 41%1).Following the April data cut-off, four additional response evaluable patients yielded an unconfirmed ORR of 61% (n=26) including two confirmed complete responses and six confirmed partial responses. To date, 58% of evaluable patients remain i...